Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
0
Authors
Toni Choueiri
Toni Choueiri•Yoshihiko Tomita•Robert Motzer
Published
March 3, 2021
Abstract
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.
